U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07382752) titled 'Decoupling Immunotherapy Toxicity and Cancer Response' on Jan. 26.
Brief Summary: This study is a novel evaluation of cardiotoxicity after ICI therapy based on traditional CV risk factors with the addition of metabolomic profiles, epigenetic aging, and CHIP. It is not an extension of previous work in ICI therapy.
Study Start Date: Jan. 09
Study Type: OBSERVATIONAL
Condition:
Tumor
Cardiovascular
Recruitment Status: RECRUITING
Sponsor: M.D. Anderson Cancer Center
Published by HT Digital Content Services with permission from Health Daily Digest....